NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis $13.53 -0.23 (-1.67%) Closing price 08/5/2026 04:00 PM EasternExtended Trading$13.60 +0.07 (+0.54%) As of 08/5/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Summit Therapeutics Stock (NASDAQ:SMMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Summit Therapeutics alerts:Sign Up Key Stats Today's Range$13.44▼$13.9650-Day Range$12.55▼$17.5452-Week Range$12.25▼$30.05Volume3.15 million shsAverage Volume3.69 million shsMarket Capitalization$10.79 billionP/E RatioN/ADividend YieldN/APrice Target$26.15Consensus RatingHold Company Overview Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies. Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration. Alongside its infectious disease program, Summit has explored small‐molecule therapies for rare genetic disorders, leveraging its drug discovery capabilities to identify compounds that modulate disease‐relevant pathways. Founded in 2003 and headquartered in Oxford, England, Summit maintains operations in North America to support clinical development and regulatory activities across the United States and Europe. The company’s management team brings extensive experience in biopharmaceutical research, clinical operations, and commercialization strategy, with a commitment to advancing its pipeline toward regulatory approval and broad patient access.AI Generated. May Contain Errors. Read More Summit Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreSMMT MarketRank™: Summit Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 165th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingSummit Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 1 strong buy rating, 7 buy ratings, 6 hold ratings, and 2 sell ratings.Upside PotentialSummit Therapeutics has a consensus price target of $26.15, representing about 93.3% upside from its current price of $13.53.Amount of Analyst CoverageSummit Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Summit Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($1.20) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -12.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -12.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 17.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Summit Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.15% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 11.02, which indicates bearish sentiment.Change versus previous monthShort interest in Summit Therapeutics has recently decreased by 6.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.62 News SentimentSummit Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Summit Therapeutics this week, compared to 5 articles on an average week.Search Interest24 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Summit Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $103,616,900.00 in company stock, which represents 0.9600% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $103,616,900.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders83.50% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.61% of the stock of Summit Therapeutics is held by institutions.Read more about Summit Therapeutics' insider trading history. Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SMMT Stock News HeadlinesSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder CancerAugust 5 at 12:50 PM | finance.yahoo.comJim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical StockAugust 4 at 8:15 AM | benzinga.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end. | Banyan Hill Publishing (Ad)Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Hold" by AnalystsAugust 3 at 4:15 AM | americanbankingnews.comSummit Therapeutics: Upgrading To Hold As Critical Approval Decision ApproachesJuly 31, 2026 | seekingalpha.comWhat is HC Wainwright's Forecast for SMMT FY2026 Earnings?July 31, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)July 30, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)July 29, 2026 | theglobeandmail.comSee More Headlines SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed this year? Summit Therapeutics' stock was trading at $17.49 at the start of the year. Since then, SMMT shares have decreased by 22.6% and is now trading at $13.53. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics PLC (NASDAQ:SMMT) posted its quarterly earnings results on Thursday, July, 23rd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.01. Read the conference call transcript. When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Top institutional investors of Summit Therapeutics include Tema ETFs LLC (0.02%) and Handelsbanken Fonder AB (0.01%). Insiders that own company stock include Mahkam Zanganeh, Robert W Duggan, Yu Xia, Manmeet Singh Soni and Ankur Dhingra. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings7/23/2026Today8/06/2026Next Earnings (Estimated)10/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 SMMT's financial health is in the Yellow zone, according to TradeSmith. SMMT has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SMMT CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees110Year Founded2003Price Target and Rating Average Price Target for Summit Therapeutics$26.15 High Price Target$40.00 Low Price Target$7.70 Potential Upside/Downside+93.3%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.08 billion Net MarginsN/A Pretax MarginN/A Return on Equity-168.94% Return on Assets-141.92% Debt Debt-to-Equity RatioN/A Current Ratio6.96 Quick Ratio6.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book17.13Miscellaneous Outstanding Shares797,750,000Free Float131,629,000Market Cap$10.79 billion OptionableOptionable Beta-1.23 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:SMMT) was last updated on 8/6/2026 by MarketBeat.com Staff. From Our PartnersSomething dark just appeared in AmericaCapitalism's net favorability has collapsed from plus 30 to plus 4 in just seven years, and it's not only Demo...Porter & Company | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredControl 100 shares without spending thousands of dollarsWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredPalantir’s 1,540% vs 32,481% company no one’s talking aboutPalantir investors who bought at IPO are sitting on gains near 1540%. But Mode Mobile, still private, has alre...Mode Mobile | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
